It consist of History of pharmaceutical industry, company history, prominent companies in market, SWOT analysis, Findings , Learning , Growth rate , Organisational Structure , Ownership Pattern etc.

1. Cipla Ltd.
Pharmaceutical Industry
MR. AJIT R. KULKARNI
ROLL NO : 31
GUIDED BY : DR. ABHIJEET BIRARI
1

2. Industry Profile
History :
1 st Drug store was opened by “Arabian Pharmacists” in Baghdad
in 1754.
Most of the today’s major pharmaceutical co.’s were founded in
the late 19th century and early 20th centuries.
Key discoveries was insulin and penicillin.
1st Pharma Company In India : Bengal Chemicals And
Pharmaceuticals Limited(BCPL) was established in 1901. This
company Started its business with a capital of Rs.700
2

3. Growth :
3

4. Some Prominent companies in the industry & their
performance :
 Lupin.
 Sun Pharma.
 Abbott India.
 Glenmark Pharma Limited
 Mankind Pharma Ltd.
4

5. 5

6. Company Profile
Background & Inception of the company :
 Cipla is a public company based in mumbai,India.
 Founded by Khwaja Abdul Hamied as THE CHEMICAL,INDUSTRIAL
AND PHARMACEUTICAL LABORATORIES(CIPLA) in the year 1935.
 1939: Mahatma Gandhi visits Cipla and inspires Cipla's founder to make
essential medicines for the nation and help make it self-reliant
6

7.  1994: Launches the world's first oral iron chelator
 1996: Makes the world's first transparent dry powder inhaler
Nature Of The Business Carried Out :
Cipla is a leading Global pharmaceutical company, dedicated to high quality,
branded and generic medicines. Cipla trusted by HealthCare professionals and
patients across geographies. Over the last 8 decade Cipla strengthened our
leadership in India's pharmaceutical industry and fortified our promise of
caring for life.
Cipla now strengthening our Global focus by consolidating and deepening our
presence in the key markets of India, South Africa and the United States, and
other Economics of the emerging world.
Cipla state-of-the-art manufacturing facility are cGMP complaint in conformity
with National and international standards. several dosage forms and API are
manufactured at these facilities continues to be approved by major
International regulatory Agencies including the United States FDA, MHRA
(UK). TGA (Australia) Federal Ministry of Health Germany, MCC the
department of health (Canada) INVIMA (Columbia) ANVISA (Brazil), the
Danish Medical Agency, WHO and Ministry of Health of various countries.
7

8. Product/Service Profile :
1.Cardiovascular : Atorlip 10 MG Tablet
2 Childerns’s Health : Cefoprox 100 MG Dry Syrup
3 Dermatology & Cosmetology : FourDerm cream
4 Diabetes : Metfor Tablet.
5 HIV/AIDS : Tenvir Tablet.
6 Hepatitis : Hepcvel Tablets
7 Infection Diseases & Critical Care : Terbicip Tablet
8 Malaria : Mosgard Tablet.
etc
P
r
a
c
t
o
P
r
a
c
t
o
8

9. Area Of Operation :
Global :
Cipla has a wide presence internationally covering south east asia, Middle East,
Latin America, Africa, Australia, New Zealand and Russia. The company offers a
diverse range of more than 1000 products in over 100 countries.
National :
The commitment to high quality standards has made Cipla the most trusted brand
and top Indian pharma company among Healthcare professional. Cipla today has
12 division reaching out to more than 20 specialities from general practitioner to
super specialist. Cipla is a market leader in three therapies-respiratory, urology &
antiretroviral with seven brands in in the top hundred list
Rural :
In the fiercely competition Indian pharmaceutical industry environment, cipla
score over with strong brand eqity, product range, unit dosage forms, pioneering
work across therapeutic areas, numerous medico marketing initiative, strong
distribution network of distribution deports scattering to network of over 3,000
stockist, reaching about 7 lakh chemist and more than 10000 colleagues with can
do attitude
9

10. Dr. Y. K. Hamid
( Chairman )
Mr. M. K. Hamid
( Vice Chairman )
Mr. Umang Vohra
( MD , Global CEO )
Mr. S. Radhakrishanan
(Non Executive Director )
Mr. Ashok Sinha
( Independent Director )
Mr. Peter Mugyenyl
( Independent Director )
Mr. Adil Zainulbhal
( Independent Director )
Organizational Structure :
10

11. Ownership Pattern :
11

12. Financial Condition :
12

13. SWOT Analysis :
Strength:
1. Has developed good positive image by providing support to cancer patients by issuing
drug at low cost
2. Imminent commencement of the fixed dose combination for treatment of uncomplicated
Malaria to tackle the more than 200 million cases globally.
3. Initiation of no touch breast scan, a step forward in the screening technology in India.
4. A foremost player in anti infective and anti asthematic formulations.
Weakness :
1. Strong competition from International and Domestic giant means Limited market share.
2. Had faced problem during negative company by AHF.
Opportunity :
1. Can venture into Alzheimer's disease medication.
2. Increased investment in the budding markets, to push expansion in the global economy.
Threats :
1. Constant price rises in India.
2. Depreciation of Indian Rupee as compared to US dollar, fluctuation in currency exchange
rates.
13

14. Findings :
 Cipla is the major pharmaceutical company from the India. It has 16 no. of
branches in their production house.
 Cipla mainly working in pharmaceutical devision from last 70 years.
 Cipla Limited generated around 101 million U.S. dollars in revenue from its
Active Pharmaceutical Ingredient business.
 Cipla earned around 164 billion Indian rupees as income from operations in
the fiscal year 2019.
14

15. Learning Experience :
 I have got information about the Industry & company.
 I have learned how to collect the secondary data.
 I have learned how to prepare the project.
 This project helps me to know the variety of products of Cipla.
 This project helps me to know how to identify opportunity to conduct
business.
15